Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Up Almost 2,000% in 2020, Is Vaxart Still a Buy?

By Jason Hawthorne - Dec 10, 2020 at 12:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A COVID-19 vaccine in tablet form would be a game-changer in the fight against the pandemic.

In the race to develop vaccines against COVID-19, various pharmaceutical and biotech companies have made use of a number of innovative methods. Messenger-RNA vaccines. Electroporation devices that deliver DNA plasmid vaccines directly into patients' cells. And, in the case of Vaxart ( VXRT -8.70% ), a coronavirus vaccine that can be taken orally in tablet form.

Assuming that it eventually proves effective and passes regulatory muster, Vaxart's tablet could become one of the best ways to get people vaccinated in the developing world, where logistics are more difficult and healthcare providers have limited access to the cold storage facilities that the leading injectable vaccine candidates require.

With Vaxart stock up by around 1,980% year to date, is there still room for new investors to profit?

A doctor handing. patient pills

Image source: Getty Images

Does it work?

Vaxart's tablet-based vaccine work didn't begin with the SARS-CoV-2 virus. The company was previously working on an oral vaccine for seasonal flu. In fact, Vaxart published results from its Phase 2 trials of that candidate just as the coronavirus was beginning to trek around the globe. That study showed the company's offering was slightly more effective in preventing the flu than market-leader Sanofi's ( SNY 1.04% ) Fluzone. 

Understandably given the circumstances, Vaxart shifted focus rapidly to the fight against COVID-19. By February, it had developed three candidates, and by May, had narrowed its efforts down to one for further testing. Results in hamsters -- which provide a good proxy for the human immune system -- showed positive results, and in October, the company inoculated the first humans in its Phase 1 trial.

What lies ahead?

Vaxart has lined up manufacturing partnerships with Emergent Biosolutions ( EBS 0.24% ), Kindred Biosciences ( KIN ), as well as Attwill Medical Solutions, should its vaccine eventually receive approval. Management expects to have phase 1 trial results by January. In the meantime, the company will have to respond to lawsuits alleging it inflated its relationship with Operation Warp Speed so that insiders could gain from the spike in stock price.

Given its successes thus far in developing a flu vaccine, and its ability to transfer what it learned in that process to the development of a SARS-CoV-2 vaccine, Vaxart has the potential to become a key global player in the fight against the coronavirus. Investing in small biotechs is a gamble, but I think Vaxart's overwhelming potential outweighs the risks. However, due to those risks and the large number of competitors working toward similar goals, I would keep my position in the stock small.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vaxart, Inc. Stock Quote
Vaxart, Inc.
VXRT
$5.77 (-8.70%) $0.55
Sanofi Stock Quote
Sanofi
SNY
$47.56 (1.04%) $0.49
Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
EBS
$41.99 (0.24%) $0.10
Kindred Biosciences, Inc. Stock Quote
Kindred Biosciences, Inc.
KIN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.